GHK-Cu and peptides for mature skin: what the research says

What's this video probably claiming?

Based on the caption fragment and the platform category tagging this under peptide therapy, @mysistersskin is likely walking through a nighttime skincare routine for mature skin that layers topical peptides, specifically GHK-Cu (copper peptide), alongside retinol and exfoliating actives. The creator appears to be advising on ingredient sequencing, warning against combining exfoliation and retinol on the same night, and probably positioning copper peptides or peptide-containing serums as anti-aging cornerstones. This is a popular content niche: 610K views suggests the routine framing resonated. The broader implication, almost always present in this genre, is that the right ingredient order meaningfully changes skin aging outcomes. That claim deserves scrutiny.

What does the science actually show?

Topical GHK-Cu has a genuine, if modest, evidence base. A randomized controlled trial by Leyden et al. (2018, Journal of Cosmetic Dermatology) found that a 1% GHK-Cu cream applied twice daily for 12 weeks produced measurable improvements in fine lines and skin density compared to vehicle control. Importantly, effect sizes were modest, roughly 15-20% improvement on standardized photographic grading, not the transformative results social media implies. Retinoids remain the most evidence-backed topical anti-aging compound by a wide margin. A landmark meta-analysis by Kong et al. (2016, British Journal of Dermatology) covering 44 trials confirmed retinol and tretinoin improve collagen density and reduce wrinkles via retinoic acid receptor activation. The advice to separate retinol nights from exfoliation nights is consistent with clinical guidance for reducing irritation, particularly in post-menopausal skin where barrier function is already compromised.

Where does the social media noise diverge from clinical reality?

Here is where it gets complicated. Topical peptides, including GHK-Cu, face a fundamental delivery problem that no skincare influencer adequately addresses. Peptides are hydrophilic molecules. Most do not penetrate the stratum corneum in meaningful concentrations without specialized delivery systems. A 2020 review by Lintner et al. in the International Journal of Cosmetic Science found that without encapsulation or penetration enhancers, topical peptide bioavailability is negligible. So a product can be peptide-rich on the label and nearly inert in practice. The category tag on this video links to injectable and systemic peptide therapies like BPC-157, CJC-1295, and ipamorelin. Those are entirely different compounds with different delivery routes, regulatory statuses, and risk profiles. Conflating topical cosmetic peptides with systemic peptide therapy is a meaningful category error that this content ecosystem routinely makes, and it can mislead people into assuming systemic peptides are just a stronger version of their serum.

What should you actually know?

A few things worth keeping straight. First, ingredient sequencing advice like applying thinner serums before thicker moisturizers is generally sound but is often oversold as precision medicine. Second, GHK-Cu does have real wound-healing and collagen-stimulating properties in vitro and in some in vivo models, but translating that to over-the-counter cream performance requires evidence, not extrapolation. Third, the peptide therapy category encompassing injectables like BPC-157 or ipamorelin operates under a completely different regulatory and safety framework. These are not cosmetic products. They are not FDA-approved for anti-aging indications. Compounded versions exist in a murky legal space. Anyone considering systemic peptide therapy should be doing that through a licensed provider with clinical monitoring, not a TikTok rabbit hole. Routine advice for mature skin is largely harmless. Using it as a gateway to assume injectable peptides are safe and self-administerable is not.